Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis

医学 恩替卡韦 内科学 危险系数 肝细胞癌 荟萃分析 置信区间 入射(几何) 胃肠病学 子群分析 乙型肝炎 倾向得分匹配 替诺福韦 乙型肝炎病毒 免疫学 拉米夫定 人类免疫缺陷病毒(HIV) 病毒 物理 光学
作者
Bao-Hong Yuan,Ru-Hong Li,Rong‐Rui Huo,Min Jun Li,George Papatheodoridis,Jian Hong Zhong,Bao-Hong Yuan,Ru-Hong Li,Rong‐Rui Huo,Min Jun Li,George Papatheodoridis,Jian Hong Zhong
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
卷期号:37 (5): 782-794 被引量:26
标识
DOI:10.1111/jgh.15783
摘要

Abstract Background and Aim Previous smaller meta‐analyses comparing the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) provided controversial results. This updated meta‐analysis aimed to reliably identify any difference in the HCC incidence between TDF‐treated or ETV‐treated CHB patients in general or in specific subgroups. Methods PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for relevant studies with hazard ratios (HRs) for HCC between TDF‐treated and ETV‐treated CHB patients. Retrieved dates ranged from January 2009 to October 2021. HRs with or without adjustment were pooled with random‐effects model. Results Twenty‐four comparative studies involving 37 771 CHB patients treated with TDF and 72 094 treated with ETV were included. TDF was associated with lower risk of HCC compared with ETV, with pooled unadjusted HR of 0.76 (95% confidence interval [CI]: 0.67–0.86) (24 studies) and adjusted HR of 0.81 (95% CI: 0.72–0.91) (21 studies). In propensity score matching cohorts, the TDF superiority was confirmed for unadjusted HR 0.83 (95% CI: 0.71–0.97) (14 studies) and was close to significance for adjusted HR (0.78, 95% CI: 0.58–1.04) (8 studies). Subgroup analyses showed that TDF was associated with lower HCC risk than ETV treatment in CHB patients who were from Asia (adjusted HR: 0.76, 95% CI: 0.66–0.87; 15 studies) or nucleos(t)ide naïve (adjusted HR:0.74, 95% CI: 0.65–0.84; 18 studies). Conclusion Current evidence from a sizable population suggests that TDF is associated with significantly lower HCC risk compared with ETV treatment in patients who are from Asia and/or nucleos(t)ide naïve.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ygm完成签到,获得积分10
刚刚
yhwang_smu发布了新的文献求助10
1秒前
superZ完成签到,获得积分10
1秒前
郭天浩完成签到,获得积分10
1秒前
2秒前
李星云完成签到,获得积分10
2秒前
2秒前
HaohaoLi完成签到,获得积分10
3秒前
minkeyantong完成签到 ,获得积分10
3秒前
只只完成签到,获得积分10
3秒前
ZZU1997发布了新的文献求助10
3秒前
3秒前
YY发布了新的文献求助10
3秒前
研友_24789完成签到,获得积分10
3秒前
Janmy完成签到,获得积分10
4秒前
W10完成签到,获得积分10
4秒前
大个的应助被科研路顺遂采纳,获得10
4秒前
秋风的应助被幸福曼岚采纳,获得10
4秒前
完美萤发布了新的文献求助30
5秒前
5秒前
温婉的荷花完成签到,获得积分10
5秒前
初景发布了新的文献求助10
5秒前
夏歌蝉完成签到,获得积分10
6秒前
书写笔迹发布了新的文献求助10
6秒前
6秒前
干鞅完成签到,获得积分10
7秒前
邱燈完成签到,获得积分10
7秒前
雷卿发布了新的文献求助10
8秒前
小森林发布了新的文献求助30
8秒前
8秒前
吴阳完成签到,获得积分10
9秒前
9秒前
9秒前
9秒前
杨三多完成签到,获得积分10
9秒前
乐乐发布了新的文献求助10
9秒前
shirley完成签到,获得积分10
10秒前
10秒前
回音发布了新的文献求助50
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162